GlassScriptPhysician profile
Ashok G Dholakia
NPI 1568451490
$4,367.35
in general payments reported to CMS, 2019-2025
32 companies · $728 in 2025
The $728 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.82 · 2020: $40.44 · 2021: $396 · 2022: $798 · 2023: $1,395 · 2024: $971 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,093.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $636.94 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $530.20 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $515.89 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $321.36 | 2021-2025 | Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $274.35 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $273.44 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.83 | 2021-2025 | Jardiance |
| Boston Scientific Corporation | $170.49 | 2023 | Exalt Model D |
| Mylan Specialty L.P. | $126.91 | 2022-2024 | Yupelri |
| Pfizer INC. | $119.03 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $114.00 | 2021-2025 | Spravato, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.45 | 2021-2023 | Xifaxan |
| Exact Sciences Corporation | $97.02 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $94.40 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $77.34 | 2020-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $75.20 | 2023 | Rexulti |
| Sumitomo Pharma America, INC. | $72.83 | 2024-2025 | Gemtesa |
| Amgen INC. | $58.72 | 2024-2025 | Krystexxa, Evenity, Repatha |
| Kowa Pharmaceuticals America, INC. | $56.51 | 2021-2023 | Seglentis, Livalo |
| Takeda Pharmaceuticals U.S.A., INC. | $55.14 | 2022-2023 | Gattex |
| Astellas Pharma US INC | $51.42 | 2022-2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $41.89 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $34.18 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.96 | 2022 | |
| Radius Health, INC. | $27.73 | 2024 | Tymlos |
| Corcept Therapeutics | $24.81 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $24.19 | 2025 | Vaxneuvance, Capvaxive, M-M-R II |
| Allergan, INC. | $21.89 | 2019 | |
| Esperion Therapeutics, INC. | $20.26 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.67 | 2022 | |
| Abbott Laboratories | $17.04 | 2021 | |
| Amarin Pharma, INC. | $12.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Dholakia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.